It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction
Headache is one of the most frequent neurologic manifestations in COVID-19. We aimed to analyze which symptoms and laboratory abnormalities were associated with the presence of headache and to evaluate if patients with headache had a higher adjusted in-hospital risk of mortality.
Methods
Retrospective cohort study. We included all consecutive patients admitted to the Hospital with confirmed SARS-CoV-2 infection between March 8th and April 11th, 2020. We collected demographic data, clinical variables and laboratory abnormalities. We used multivariate regression analysis.
Results
During the study period, 576 patients were included, aged 67.2 (SD: 14.7), and 250/576 (43.3%) being female. Presence of headache was described by 137 (23.7%) patients. The all-cause in-hospital mortality rate was 127/576 (20.0%). In the multivariate analysis, patients with headache had a lower risk of mortality (OR: 0.39, 95% CI: 0.17–0.88, p = 0.007). After adjusting for multiple comparisons in a multivariate analysis, variables that were independently associated with a higher odds of having headache in COVID-19 patients were anosmia, myalgia, female sex and fever; variables that were associated with a lower odds of having headache were younger age, lower score on modified Rankin scale, and, regarding laboratory variables on admission, increased C-reactive protein, abnormal platelet values, lymphopenia and increased D-dimer.
Conclusion
Headache is a frequent symptom in COVID-19 patients and its presence is an independent predictor of lower risk of mortality in COVID-19 hospitalized patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Hospital Clínico Universitario de Valladolid, Department of Neurology, Valladolid, Spain (GRID:grid.411057.6) (ISNI:0000 0000 9274 367X)
2 Universidad de Valladolid, Imaging Processing Laboratory, Valladolid, Spain (GRID:grid.5239.d) (ISNI:0000 0001 2286 5329)
3 Hospital Clínico Universitario de Valladolid, Department of Neurology, Valladolid, Spain (GRID:grid.411057.6) (ISNI:0000 0000 9274 367X); University of Valladolid, Department of Medicine, Valladolid, Spain (GRID:grid.5239.d) (ISNI:0000 0001 2286 5329); Universidad de Valladolid – Consejo Superior de Investigaciones Científicas, Neurovascular Research Laboratory. Instituto de Biología y Genética Molecular, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846)
4 Hospital Clínico Universitario de Valladolid, Department of Neurology, Valladolid, Spain (GRID:grid.411057.6) (ISNI:0000 0000 9274 367X); University of Valladolid, Department of Medicine, Valladolid, Spain (GRID:grid.5239.d) (ISNI:0000 0001 2286 5329)